FrancophonIA/ELRC3.0 huggingface dataset:
English: A decision to use this vaccine before or after any other veterinary medicinal product therefore needs to be made on a case by case basis.
Croatian: Odluku o primjeni ovog cjepiva prije, odnosno poslije primjene bilo kojeg drugog veterinarsko-medicinskog proizvoda treba donositi od slučaja do slučaja.
English: In individual pigs the temperature increase after associated use may commonly exceed 2°C.
Croatian: Kod pojedinih svinja može doći do povećanja temperature nakon zajedničke primjene više od 2°C.
English: 2 Relative potency units defined against a reference vaccine.
Croatian: 2 Relativne jedinice potentnosti, određene prema referentnom cjepivu.
English: A single dose of 2 ml in pigs starting at 3 weeks of age.
Croatian: Jedna doza od 2 ml za svinje od 3. tjedna starosti.
English: Emulsion for injection
Croatian: Emulzija za injekciju
English: Store in a refrigerator.
Croatian: 11. POSEBNI UVJETI ČUVANJA Čuvati u hladnjaku.
English: To reduce the loss of daily weight gain during the finishing period in face of infections with Mycoplasma hyopneumoniae and/or PCV2 (as observed in field studies).
Croatian: Za smanjenje gubitka dnevnog prirasta u kasnom stadiju infekcije s Mycoplasma hyopneumoniae i/ili PCV2 (kao što je primijećeno u terenskim ispitivanjima).
English: Milton Keynes Buckinghamshire MK7 7AJ
Croatian: Milton Keynes Buckinghamshire
English: Homogenous white to nearly white emulsion after shaking.
Croatian: Nakon protresanja homogena bijela do bjelkasta emulzija.
English: Porcilis PCV M Hyo emulsion for injection for pigs
Croatian: Porcilis PCV M Hyo emulzija za injekciju za svinje
English: IM
Croatian: I
English: Mild systemic reactions may uncommonly be observed up to one day after vaccination and consist of being less active, a tendency of the animal to lie down and minor signs of discomfort.
Croatian: Blage sustavne reakcije rijetko mogu biti zamijećene do 1 dan nakon cijepljenja, životinja je manje aktivna, sklona ležanju te pokazuje manje znakove nelagode.
English: PCV2 ORF2 subunit antigen ≥ 2,828 AU M. hyopneumoniae inac.
Croatian: PCV2, ORF2 subjedinice antigena ≥ 2828 AU, M. hyopneumoniae inac.
English: Shelf life after first opening the immediate packaging: 8 hours.
Croatian: Rok valjanosti poslije prvog otvaranja unutarnjeg pakovanja: 8 sati.
English: Porcine circovirus type 2 (PCV2) ORF2 subunit antigen ≥ 2,828 AU1 Mycoplasma hyopneumoniae J strain inactivated
Croatian: Cirkovirus svinja tip 2 (PCV2), ORF2 subjedinica antigena ≥ 2828 AU1 Mycoplasma hyopneumoniae, J inaktivirani soj
English: days after vaccination.
Croatian: 2 tjedna nakon cijepljenja.
English: 37008 Carbajosa de la Sagrada, Salamanca
Croatian: C/Zeppelin 6, Parcela 38 37008 Carbajosa de la Sagrada,
English: EU/2/14/175/001-010
Croatian: EU/2/14/175/001 (20 ml)
English: Hypersensitivity reactions after vaccination may occur uncommonly.
Croatian: Reakcije preosjetljivosti nakon cijepljenja rijetko se pojavljuju.
English: For the active immunisation of pigs to reduce viraemia, virus load in lungs and lymphoid tissues, virus shedding caused by porcine circovirus type 2 (PCV2) infection, and severity of lung lesions caused by Mycoplasma hyopneumoniae infection.
Croatian: Za aktivnu imunizaciju svinja u cilju smanjivanja viremije, nakupljanja virusa u plućima i limfoidnim tkivima, širenja virusa radi infekcije cirko virusom svinja tip 2 (PCV2) te smanjenje jačine plućnih lezija uzrokovanih infekcijom s Mycoplasma hyopneumoniae.
English: Even if small amounts have been injected, accidental injection with this product can cause intense swelling, which may, for example, result in ischaemic necrosis and even the loss of a digit.
Croatian: U slučaju nehotičnog injiciranja ovim proizvodom, čak ako je injicirana i vrlo mala količina, ona može prouzročiti intenzivno oticanje, koje, na primjer može rezultirati ishemičnom nekrozom i čak gubitkom prsta.
English: MSD Animal Health Danube Biotech GmbH Brennaustrasse 1
Croatian: ŠPANJOLSKA MSD Animal Helath Danube Biotech GmbH
English: The temperature returns to normal from 1 to 2 days after the peak temperature is observed.
Croatian: Temperatura se vraća na normalne vrijednosti jedan do dva dana nakon što je uočeno povećanje temperature.
English: 30938 Burgwedel GERMANY
Croatian: Im Langen Felde 5 30938 Burgwedel NJEMAČKA
English: M. hyopneumoniae: 21 weeks after (the last) vaccination.
Croatian: M. hyopneumoniae: 21 tjedan nakon (zadnjeg) cijepljenja
English: Burgwedel Biotech GmbH Im Langen Felde 5
Croatian: Burgwedel Biotech GmbH
English: M. hyopneumoniae: 4 weeks after vaccination.
Croatian: M. hyopneumoniae:4 tjedna nakon cijepljenja.
English: The product stimulates the development of active immunity against porcine circovirus type 2 and Mycoplasma hyopneumoniae in pigs.
Croatian: Proizvod stimulira razvoj aktivne imunosti protiv cirkovirusa svinja tip 2 i Mycoplasma hyopneumoniae kod svinja.
English: Two dose vaccination schedule:
Croatian: Dvokratni plan cijepljenja:
English: Duration of immunity (both vaccination schedules): PCV2: 22 weeks after (the last) vaccination.
Croatian: Trajanje imunosti (kod oba načina cijepljenja) PCV2: 22 tjedna nakon (zadnjeg) cijepljenja:
English: 100 ml 200 ml 500 ml
Croatian: 100 ml 200 ml
English: Poligono Industrial EI Montalvo 1 C/Zeppelin 6, Parcela 38
Croatian: Poligono Industrial EI Montalvo 1
English: The animals return to normal 1 to 2 days after the peak temperature is observed.
Croatian: Životinje se vraćaju u normalno stanje 1 do 2 dana nakon što je zamijećeno najveće povećanje temperature.
English: Transient local injection site reactions, which are restricted to a slight swelling (maximum 2 cm diameter), may commonly occur directly after vaccination, but reactions may not appear until 12 days after vaccination.
Croatian: Prolazna lokalna reakcija na mjestu aplikacije a koja je ograničena na blago oticanje ( maksimalno 2 cm) može se uočiti odmah nakon primjene, ali reakcije se mogu pojaviti tek 12 dana nakon cijepljenja.
English: Shelf life after first opening the container: 8 hours.
Croatian: Rok upotrebe nakon prvog otvaranja: 8 sati.
English: Intervet International BV Wim de Körverstraat 35 5831 AN Boxmeer The NETHERLANDS
Croatian: Wim de Korverstraat 35 5831 AN Boxmeer NIZOZEMSKA
English: Single dose vaccination schedule:
Croatian: Jednokratni plan cijepljenja:
English: Accidental -injection is dangerous.
Croatian: POSEBNO UPOZORENJE, UKOLIKO JE POTREBNO Nehotično injiciranje je opasno.
English: PACKAGE LEAFLET: Porcilis PCV M Hyo emulsion for injection for pigs
Croatian: UPUTA O VMP ZA: Porcilis PCV M Hyo emulzija za injekcije za svinje
English: The vaccine stimulates active immunity against porcine circovirus type 2 and Mycoplasma hyopneumoniae in pigs.
Croatian: Cjepivo stimulira razvoj aktivne imunosti protiv cirkovirusa svinja tip 2 i Mycoplasma hyopneumoniae kod svinja.
English: 20 ml 50 ml
Croatian: 10 x 50 ml
English: M. hyopneumoniae: 3 weeks after the second vaccination.
Croatian: M. hyopneumoniae: 3 tjedna nakon drugog cijepljenja.
English: Onset of immunity with two dose vaccination:
Croatian: Početak imunosti s jednokratnim cijepljenjem:
English: A. MANUFACTURERS OF THE BIOLOGICAL ACTIVE SUBSTANCES AND MANUFACTURER RESPONSIBLE FOR BATCH RELEASE
Croatian: PROIZVOĐAČ BIOLOŠKI DJELATNE TVARI I PROIZVOĐAČ ODGOVORAN ZA PUŠTANJE SERIJE U PROMET
English: Transient local injection site reactions, which are restricted to a slight swelling (< 2 cm diameter), may uncommonly occur.
Croatian: Rijetko se mogu pojaviti prolazne lokalne reakcije na mjestu injiciranja, koje su ograničene na blago oticanje (< 2 cm dijametralno).
English: GERMANY
Croatian: NIZOZEMSKA
English: Withdrawal period: Zero days.
Croatian: KARENCIJA Karencija: nula dana.
English: 20 ml 50 ml 100 ml 200 ml 500 ml 10x20 ml 10x50 ml 10x100 ml 10x200 ml 10x500 ml
Croatian: 10 x 100 ml 10 x 200 ml
English: SPAIN
Croatian: Salamanca
English: Special warnings for each target species: Vaccinate only healthy animals.
Croatian: Posebna upozorenja za svaku od ciljnih životinja:
English: Intervet International BV 5831 AN Boxmeer The NETHERLANDS
Croatian: NL-5831 AN Boxmeer NIZOZEMSKA
English: Cardboard box with 10 vials of 20 ml.
Croatian: Kartonska kutija s 10 bočica od 20 ml.
English: MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS Vials of 20 and 50 ml
Croatian: OSNOVNI PODACI KOJI SE MORAJU NALAZITI NA MALIM UNUTARNJIM PAKOVANJIMA
English: Cardboard box with 1 vial of 20 ml.
Croatian: Kartonska kutija s 1 bočicom od 20 ml.
English: Cardboard box with 10 vials of 200 ml.
Croatian: Kartonska kutija s 10 bočica od 200 ml.
English: Cardboard box with 1 vial of 200 ml.
Croatian: Kartonska kutija s 1 bočicom od 200 ml.
English: Special precautions for use in animals: Not applicable.
Croatian: Posebne mjere opreza prilikom primjene na životinjama:
English: When PCV2 and/or M. hyopneumoniae infections occur early the two dose vaccination schedule is recommended.
Croatian: Hyopneumoniae preporuča se dvokratni plan cijepljenja.
English: PCV2: 18 days after the first vaccination.
Croatian: PCV2: 2 tjedna nakon cijepljenja.
English: Cardboard box with 1 vial of 50 ml.
Croatian: Kartonska kutija s 1 bočicom od 50 ml.
English: Cardboard box with 1 vial of 500 ml.
Croatian: Kartonska kutija s 1 bočicom od 500 ml.
English: Cardboard box with 10 vials of 100 ml.
Croatian: Kartonska kutija s 10 bočica od 100 ml.
English: Cardboard box with 10 vials of 500 ml.
Croatian: Kartonska kutija s 10 bočica od 500 ml.
English: Cardboard box with 1 vial of 100 ml.
Croatian: Kartonska kutija s 1 bočicom od 100 ml.
English: Cardboard box with 10 vials of 50 ml.
Croatian: Kartonska kutija s 10 bočica od 50 ml.
English: Onset of immunity with single dose vaccination: PCV2: 2 weeks after vaccination.
Croatian: Početak imunosti s dvokratnim planom cijepljenja: PCV2: 18 dana nakon prvog cijepljenja.
English: Marketing authorisation holder and manufacturer responsible for batch release:
Croatian: Nositelj odobrenja za stavljanje u promet i proizvođač odgovoran za puštanje serije u promet: Intervet International BV
English: Further information on Nerlynx can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Croatian: Više informacija o lijeku Nerlynx nalazi se na internetskim stranicama Agencije: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
English: It is given following treatment with trastuzumab (another medicine used for the same purpose).
Croatian: Daje se nakon liječenja trastuzumabom (još jedan lijek koji se koristi u istu svrhu).
English: The medicine is available as tablets (40 mg).
Croatian: Lijek je dostupan u obliku tableta (40 mg).
English: The recommended dose is 6 tablets (240 mg) once a day with food, preferably in the morning.
Croatian: Preporučena je doza 6 tableta (240 mg) koje se uzimaju jednom dnevno uz obrok, po mogućnosti ujutro.
English: Treatment should be started within a year of finishing treatment with trastuzumab, and is given for 1 year.
Croatian: Liječenje treba započeti unutar godine dana od završetka liječenja trastuzumabom, a traje jednu godinu.
English: What measures are being taken to ensure the safe and effective use of Nerlynx?
Croatian: Koje se mjere poduzimaju kako bi se osigurala sigurna i učinkovita primjena lijeka Nerlynx?
English: The most common serious side effects are diarrhoea and vomiting.
Croatian: Najčešće ozbiljne nuspojave jesu proljev i povraćanje.
English: Other common side effects (which may affect more than 1 in 10 people) are nausea (feeling sick), vomiting, tiredness, belly pain, rash, decreased appetite, stomatitis (sore, inflamed mouth), and muscle spasms.
Croatian: Druge nuspojave (koje se mogu pojaviti u više od 1 na 10 osoba) jesu mučnina, povraćanje, umor, bol u trbuhu, osip, smanjeni apetit, stomatitis (bolna, upaljena usta) i grčevi mišića.
English: Other information about Nerlynx
Croatian: Ostale informacije o lijeku Nerlynx
English: Because HER2 helps cancer cells to grow and divide, blocking it helps to stop these cells growing and prevents the cancer from coming back.
Croatian: Budući da HER2 doprinosi rastu i dijeljenju stanica raka, njegovim blokiranjem pomaže se zaustaviti rast tih stanica i sprječava povratak raka.
English: The doctor may reduce the dose or stop treatment if a patient has severe side effects, including diarrhoea.
Croatian: Liječnik će možda smanjiti dozu ili zaustaviti liječenje ako bolesnica ima teške nuspojave, uključujući proljev.
English: It must also not be used with certain medicines that affect the way Nerlynx is broken down in the body.
Croatian: Također se ne smije primjenjivati u bolesnika koji uzimaju određene druge lijekove koji utječu na način na koji se Nerlynx razgrađuje u tijelu.
English: The doctor may also modify the dose if Nerlynx is given with certain other medicines.
Croatian: Također, liječnik će možda promijeniti dozu ako se Nerlynx daje uz neke druge lijekove.
English: Nerlynx must not be used in patients with severely reduced liver function.
Croatian: Lijek Nerlynx ne smiju uzimati bolesnici s ozbiljno smanjenom jetrenom funkcijom.
English: Why is Nerlynx authorised in the EU?
Croatian: Zašto je lijek Nerlynx odobren u EU-u?
English: Side effects reported with Nerlynx are carefully evaluated and any necessary action taken to protect patients.
Croatian: Nuspojave prijavljene za lijek Nerlynx pažljivo se procjenjuju i poduzimaju se potrebne mjere za zaštitu bolesnika.
English: An overview of Nerlynx and why it is authorised in the EU
Croatian: Pregled informacija o lijeku Nerlynx i zašto je odobren u EU-u
English: When only women with hormone-receptor positive cancer were considered, about 95% of those given Nerlynx lived another year without the cancer coming back versus 91% of those given placebo.
Croatian: Ako se promatra samo žene s rakom pozitivnim na hormonski receptor, oko 95 % onih koje su uzimale Nerlynx živjele su još godinu dana bez ponovne pojave raka naspram 91 % žena koje su uzimale placebo.
English: As for all medicines, data on the use of Nerlynx are continuously monitored.
Croatian: Kao i za sve lijekove, podatci o primjeni lijeka Nerlynx kontinuirano se prate.
English: The active substance in Nerlynx, neratinib, is a type of cancer medicine called a tyrosine kinase inhibitor.
Croatian: Djelatna tvar u lijeku Nerlynx, neratinib, vrsta je lijeka protiv raka, naziva inhibitor tirozin kinaze.
English: Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Nerlynx have also been included in the summary of product characteristics and the package leaflet.
Croatian: Preporuke i mjere opreza kojih se zdravstveni radnici i bolesnici trebaju pridržavati u cilju sigurne i učinkovite primjene lijeka Nerlynx također se nalaze u sažetku opisa svojstava i u uputi o lijeku.
English: The company that markets Nerlynx will provide a guide for healthcare professionals who prescribe or dispense the medicine, and educational material for patients and carers.
Croatian: Tvrtka koja stavlja lijek Nerlynx u promet izradit će vodič za zdravstvene radnike koji propisuju ili izdaju lijek te edukacijski materijal za bolesnike i njegovatelje.
English: What are the risks associated with Nerlynx?
Croatian: Koji su rizici povezani s lijekom Nerlynx?
English: These materials will explain the effects of Nerlynx on the gut, such as diarrhoea, and how to manage them, and will give advice on the need for patients to tell their healthcare professionals of side effects.
Croatian: U tim će materijalima biti objašnjeni učinci lijeka Nerlynx na crijeva, kao što je proljev, te kako ih zbrinjavati, a uključit će i upozorenje o potrebi da bolesnici obavijeste zdravstvene radnike o nuspojavama koje imaju.
English: The European Medicines Agency considered that Nerlynx had been shown to be of benefit in women with HER2-positive early breast cancer, and that this benefit seemed to be mainly in women with hormone-receptor positive disease.
Croatian: Europska agencija za lijekove smatra da se lijek Nerlynx pokazao korisnim u žena s HER2 pozitivnim ranim stadijem raka dojke te da se ta korist uglavnom manifestira u žena s bolešću pozitivnom na hormonski receptor.
English: How is Nerlynx used?
Croatian: Kako se Nerlynx koristi?
English: The Agency therefore decided that Nerlynx's benefits are greater than its risks in this group and it can be authorised for use in the EU.
Croatian: Agencija je stoga zaključila da koristi od lijeka Nerlynx nadmašuju s njim povezane rizike te da lijek može biti odobren za primjenu u Europskoj uniji.
English: It is intended for use only in breast cancers that produce high levels of a protein called HER2, which helps cells to divide and grow (HER2-positive breast cancer), and that also have receptors (targets) for the female sex hormones (hormone-receptor positive breast cancer).
Croatian: Namijenjen je za liječenje samo raka dojke kod kojeg se proizvode visoke razine bjelančevine naziva HER2, koja pridonosi dijeljenju i rastu stanica (rak dojke pozitivan na HER2), te kod koje postoje receptori (prihvatna mjesta) ženskih spolnih hormona (rak dojke pozitivan na hormonske receptore).
English: Nerlynx treatment should be started and supervised by a doctor experienced in giving cancer medicines and can only be obtained with a prescription.
Croatian: Liječenje lijekom Nerlynx treba započeti i nadzirati liječnik iskusan u primjeni lijekova protiv raka, a lijek se izdaje samo na liječnički recept.
English: Nerlynx is a breast cancer medicine used to reduce the risk of the disease coming back in patients with early breast cancer who have had surgery.
Croatian: Nerlynx je lijek protiv raka dojke koji se upotrebljava za smanjenje rizika od ponovne pojave bolesti u bolesnica s ranim stadijem raka dojke u kojih je proveden kirurški zahvat.
English: Although the side effects, particularly diarrhoea, can be severe and lead to treatment being stopped, there would be patients with HER2-positive, hormone-receptor positive early breast cancer for whom treatment with Nerlynx after surgery and trastuzumab would be a reasonable option.
Croatian: Iako nuspojave, osobito proljev, mogu biti teške i dovesti do prestanka liječenja, za neke je bolesnike i to osobito one s rakom dojke u ranoj fazi pozitivnim na HER2, pozitivnim na hormonske receptore, liječenje lijekom Nerlynx nakon kirurškog zahvata i terapije trastuzumabom opravdana opcija.
English: What is Nerlynx and what is it used for?
Croatian: Što je Nerlynx i za što se primjenjuje?
English: It attaches to the HER2 protein on the cancer cells, and so blocks its action.
Croatian: Djelatna tvar veže se na bjelančevinu HER2 na stanicama raka te tako blokira njeno djelovanje.
English: Around 94% of the women given a year's treatment with Nerlynx lived for 1 further year after stopping Nerlynx without their cancer coming back versus 92% of those given placebo.
Croatian: U otprilike 94 % žena koje su godinu dana primale terapiju lijekom Nerlynx, u sljedećoj godini nakon prestanka terapije lijekom Nerlynx nije došlo do ponovne pojave raka naspram 92 % žena koje su uzimale placebo.
English: For more information about using Nerlynx, see the package leaflet or contact your doctor or pharmacist.
Croatian: Više informacija o primjeni lijeka Nerlynx pročitajte u uputi o lijeku, odnosno obratite se liječniku ili ljekarniku.
English: The most common side effect with Nerlynx is diarrhoea, which affects nearly all patients.
Croatian: Najčešća nuspojava lijeka Nerlynx je proljev i ona zahvaća gotove sve bolesnike.
English: What benefits of Nerlynx have been shown in studies?
Croatian: Koje su koristi od lijeka Nerlynx utvrđene u ispitivanjima?
English: For the full list of restrictions, see the package leaflet.
Croatian: Potpuni popis ograničenja vezanih uz primjenu potražite u uputi o lijeku.
English: For the full list of side effects of Nerlynx, see the package leaflet.
Croatian: Potpuni popis nuspojava zabilježenih pri primjeni lijeka Nerlynx potražite u uputi o lijeku.
English: How does Nerlynx work?
Croatian: Kako djeluje Nerlynx?
English: Nerlynx has been shown to be more effective than placebo (a dummy treatment) at preventing the cancer from coming back in one main study involving 2,840 women with HER2-positive early breast cancer who had already received trastuzumab.
Croatian: U jednom glavnom ispitivanju u koje je bilo uključeno 2840 žena s HER2 pozitivnim ranim stadijem raka dojke koje su već primile trastuzumab, pokazalo se da je Nerlynx učinkovitiji od placeba (prividno liječenje) u sprječavanju ponovne pojave raka.
English: Patients are given treatment to prevent diarrhoea when starting Nerlynx.
Croatian: Kada započnu terapiju lijekom Nerlynx bolesnice dobiju lijekove za sprječavanje proljeva.
English: Strength Pharmaceutical form
Croatian: Farmaceutski oblik
English: Target species
Croatian: Ciljna vrsta životinja
English: --1 Live myxoma vectored RHD virus strain 009: ≥103.0 and ≤106.1 FFU* *Focus Forming Units
Croatian: --1 Živi miksoma virus, vektorski RHD soj 009: ≥10
English: Packaging
Croatian: Pakovanje
English: Content
Croatian: Sadržaj
English: EU (MA) number Invented name
Croatian: Izmišljeni naziv
English: Lyophilisate: vial (glass); Solvent: vial (PET)
Croatian: Liofilizat: bočica (staklena) i Otapalo: bočica (PET)
English: Package size Withdrawal period
Croatian: Veličina pakovanja
English: Lyophilisate: vial (glass); Solvent: vial (glass)
Croatian: Liofilizat: bočica (staklena) i Otapalo: bočica (staklena)
English: Lyophilisate: 5 vials; Solvent: 5 vials
Croatian: 25 bocica ; Otapalo: 25 bočica
English: 250 mg Film-coated tablet Oral use
Croatian: 250 mg Filmom obložena tableta
English: Blister (PVC/PE/PCTFE/ALU)
Croatian: Blister (PVC/PE/PCTFE/Al) 56 tableta (višestruko pakiranje)
English: MA(EU) Number
Croatian: Broj (EU) odobrenja (Zaštićeno) ime
English: Immediate Packaging Pack size
Croatian: Put primjene Unutarnje pakiranje Veličina pakiranja
English: Table A:
Croatian: Tablica A:
English: Haematology: No interference.
Croatian: Hematologija: Nema interferencija.
English: It is eliminated from the plasma in 5-7 days.
Croatian: Eliminira se iz plazme za 5-7 dana.
English: 125 ml - 5years
Croatian: 125 ml - 5 godine
English: Date of first authorisation: 29/11/1999 Date of last renewal: 01/10/2009
Croatian: Datum prvog odobrenja: 29/11/1999 Datum posljednjeg produljenja odobrenja: 01/10/2009
English: The use in such animals is not recommended.
Croatian: Primjena na takvim životinjama se ne preporučuje.
English: Do not overheat > 37 °C.
Croatian: Ne pregrijavati > 37 °C.
English: Use within 24 hours.
Croatian: Primijeniti u roku od 24 sata.
English: <EXP {month/year}>
Croatian: <EXP {mjesec/godina}>
English: Do not store above 30 °C.
Croatian: Ne čuvati iznad 30 °C.
English: The plasma half-life is 30-40 hours.
Croatian: Poluživot eliminacije iz plazme je 30-40 sati.
English: For any information about this veterinary medicinal product, please contact the local representative of the marketing authorisation holder.
Croatian: Za bilo koju informaciju o ovom veterinarsko-medicinskom proizvodu molimo da kontaktirate lokalnog zastupnika nositelja odobrenja za stavljanje u promet.
English: 1043EJ, Amsterdam The Netherlands
Croatian: 1043EJ, Amsterdam
English: <Batch> <Lot> {number}
Croatian: <Serija> <Lot> {broj}
English: Keep out of the reach and sight of children.
Croatian: Čuvati izvan dosega i pogleda djece.
English: In certain clinical situations, a dosage of 15-30 ml/kg may be appropriate.
Croatian: U određenim kliničkim situacijama, možda će biti prikladna doza od 15-30 ml/kg.
English: Shelf-life of the veterinary medicinal product as packaged for sale: 60 ml - 3 years
Croatian: Rok valjanosti veterinarsko-medicinskog proizvoda kad je zapakiran za prodaju: 60 ml - 3 godine
English: Do not use after the expiry date stated on the label.
Croatian: Ne koristiti poslije isteka roka valjanosti naznačenog na etiketi.
English: A box with one (1) polyolefin infusion bag (containing either 60 ml or 125 ml), within an overwrap.
Croatian: Kutija s jednom (1) poliolefinskom vrećicom za infuziju (sadrži ili 60 ml ili 125 ml), u pakovanju.
English: Do not combine the contents of more than one bag.
Croatian: Ne kombinirati sadržaj sa sadržajem drugih vrećica.